A self-sufficient peroxide-driven hydroxylation biocatalyst

Angewandte Chemie - International Edition

Volumn 42, Issue 28, 2003, Pages 3299-3301

  Cirino, Patrick C ^a   Arnold, Frances H ^a  

^a CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Biocatalysis; Cytochrome P450; Enzymes; Oxidation; Peroxygenase

Indexed keywords

HYDROXYLATION; SUBSTRATES;

CELL FREE REACTION SYSTEM;

ENZYMES;

CYTOCHROME P450; HEME DERIVATIVE; OXIDOREDUCTASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ARTICLE; BIOCATALYST; BIOMIMETICS; ENZYME ACTIVITY; ENZYME SUBSTRATE; HYDROXYLATION; OXIDATION; PROTEIN DOMAIN; REACTION ANALYSIS; ROOM TEMPERATURE; STEREOCHEMISTRY; THERMOSTABILITY;

CATALYSIS; CYTOCHROME P-450 ENZYME SYSTEM; HYDROXYLATION; PEROXIDASES; PEROXIDES;

EID: 0043269709     PISSN: 14337851     EISSN: None     Source Type: Journal    
DOI: 10.1002/anie.200351434     Document Type: Article

References (42)

1. a) J. A. Labinger, J. E. Bercaw, Nature 2002, 417, 507;
2. b) R. H. Crabtree, J. Chem. Soc. Dalton Trans. 2001, 2437;
3. c) Y. Ishii, S. Sakaguchi, T. Iwahama, Adv. Synth. Catal. 2001, 343, 393;
4. d) M. Costas, K. Chen, L. Que, Coord. Chem. Rev. 2000, 200, 517;
5. e) G. B. Maravin, M. V. Avdeev, E. I. Bagrii, Pet. Chem. Ind. Dev. Annu 2000, 40, 1;
6. f) S. S. Stahl, J. A. Labinger, J. E. Bercaw, Angew. Chem. 1998, 110, 2298; Angew. Chem. Int. Ed. 1998, 37, 2181;
7. f) S. S. Stahl, J. A. Labinger, J. E. Bercaw, Angew. Chem. 1998, 110, 2298; Angew. Chem. Int. Ed. 1998, 37, 2181;
8. g) A. E. Shilov, G. B. Shul'pin, Chem. Rev. 1997, 97, 2879.
9. a) D. A. Kopp, S. J. Lippard, Curr. Opin. Chem. Biol. 2002, 6, 568;
10. b) T. H. Smits, S. B. Balada, B. Witholt, J. B. van Beilen, J. Bacteriol. 2002, 184, 1733;
11. c) M. M. Marin, T. H. Smits, J. B. van Beilen, F. Rojo, J. Bacteriol. 2001, 183, 4202;
12. d) A. Ratajczak, W. Geissdorfer, W. Hillen, Appl. Environ. Microbiol. 1998, 64, 1175.
13. P. R. Ortiz de Montellano, Cytochrome P450: Structure, Mechanism, and Biochemistry, 2nd ed., Plenum, New York, 1995.
14. H. L. Holland, H. K. Weber, Curr. Opin. Biotechnol. 2000, 11, 547.
15. a) O. Kirk, T. V. Borchert, C. C. Fuglsang, Curr. Opin. Biotechnol. 2002, 13, 345;
16. b) A. Liese, K. Seelbach, C. Wandrey, Industrial Biotransformations, Wiley-VCH, Weinheim, 2000.
17. A. Schmid, J. S. Dordick, B. Hauer, A. Kiener, M. Wubbolts, B. Witholt, Nature 2001, 409, 258.
18. a) Z. Li, J. B. van Beilen, W. A. Duetz, A. Schmid, A. de Raadt, H. Griengl, B. Witholt, Curr. Opin. Chem. Biol. 2002, 6, 136;
19. b) W. A. Duetz, J. B. van Beilen, B. Witholt, Curr. Opin. Biotechnol. 2001, 12, 419;
20. c) K. M. Koeller, C. H. Wong, Nature 2001, 409, 232.
21. D. Mansuy, Comp. Biochem. Physiol. Part C: Pharmacol. Toxicol. Endocrinol. 1998, 121, 5.
22. H. Joo, Z. Lin, F. H. Arnold, Nature 1999, 399, 670.
23. Y. Miura, A. J. Fulco, Biochim. Biophys. Acta 1975, 388, 305.
24. J. H. Capdevila, S. Wei, C. Helvig, J. R. Falck, Y. Belosludtsev, G. Truan, S. E. Graham-Lorence, J. A. Peterson, J. Biol. Chem. 1996, 271, 22663.
25. P. C. Cirino, F. H. Arnold, Adv. Synth. Catal. 2002, 344, 932.
26. Q. S. Li, J. Ogawa, S. Shimizu, Biochem. Biophys. Res. Commun. 2001, 280, 1258.
27. BMP consists of the first 463 amino acids. A 6-His sequence was included at the C-terminus with no notable effect on activity.
28. U. Schwaneberg, C. Schmidt-Dannert, J. Schmitt, R. D. Schmid, Anal. Biochem. 1999, 269, 359.
29. -1), while similar TONs are reached. As a result of evolution in DMSO, 21B3 activity is not inhibited by DMSO until concentrations exceed 10%.
30. Both HF87A and 21B3 are approximately 100% selective for the C-12 position of 12-pNCA, and result in nearly complete conversion of hydroxylated products into pNP.
31. K. G. Ravichandran, S. S. Boddupalli, C. A. Hasermann, J. A. Peterson, J. Deisenhofer, Science 1993, 261, 731.
32. F. van Rantwijk, R. A. Sheldon, Curr. Opin. Biotechnol. 2000, 11, 554.
33. CPO is reported to oxidize unactivated C-H bonds in the radical probe substrate (trans-2-phenyl-l-methylcyclopropane) with a TON of 20, where only 31% of the product was alcohol; see P. H. Toy, M. Newcomb, L. P. Hager, Chem. Res. Toxicol. 1998, 11, 816.
34. a) I. Matsunaga, T. Sumimoto, M. Ayata, H. Ogura, FEBS Lett. 2002, 528, 90;
35. b) I. Matsunaga, N. Yokotani, O. Gotoh, E. Kusunose, M. Yamada, K. Ichihara, J. Biol. Chem. 1997, 272, 23592.
36. I. Matsunaga, A. Yamada, D. S. Lee, E. Obayashi, N. Fujiwara, K. Kobayashi, H. Ogura, Y. Shiro, Biochemistry 2002, 41, 1886.
37. I. Matsunaga, A. Ueda, T. Sumimoto, K. Ichihara, M. Ayata, H. Ogura, Arch. Biochem. Biophys. 2001, 394, 45.
38. These P450s have unique active sites which include an Arg residue (see ref. [22]). Only fatty acids are accepted as substrates, and the carboxylate group of the substrate is positioned into the active site upon substrate binding. It is believed that the carboxylate group and the Arg residue work together to bind peroxide and facilitate O-O bond cleavage (see ref. [21]).
39. P. C. Cirino, F. H. Arnold, Curr. Opin. Chem. Biol. 2002, 6, 130.
40. F. P. Guengerich, Nat. Rev. Drug Discovery 2002, 1, 359.
41. A. Glieder, E. T. Farinas, F. H. Arnold, Nat. Biotechnol. 2002, 20, 1135.
42. Crude lysate or purified protein can be used.